A web-blog (formerly known as Stu's Views and MS News), now published by MS Views and News, a patient advocacy organization. The information on this blog helps to Empower those affected by Multiple Sclerosis globally, with education, information, news and community resources.
~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.
Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
Tuesday, May 12, 2015
Oral Drugs May Reduce Preference for Injectable Drugs in Multiple Sclerosis Treatment
MS is a chronic, progressive neurodegenerative disorder that results from an attack on the central nervous system (brain, spinal cord and optical nerves) by the body’s own immune system, causing inflammation and damage to the myelin layer that covers and protects neurons, leading to irreversible neurological disability. MS affects approximately 2.5 million people worldwide.
Injectable drugs comprise the largest portion of the MS drug market, although several new oral pipeline drugs are helping to establish oral drugs in the United States. According to the study, oral therapies are revolutionizing MS treatment as they offer enhanced dosing along with higher rates of patient compliance.Progressive MS is characterized by a gradual, steady progression of disability, leading to impairment in vision and walking, pain, fatigue, incontinence and cognitive changes. Patients usually have a poor response to treatment and there is little or no recovery. Progressive MS can be either primary, where patients develop this form of the disease from the time of diagnosis, or secondary, where patients initially experience a relapsing-remitting multiple sclerosis (RRMS) phase of neurological dysfunction that later evolves into a secondary progressive disease. Primary progressive MS only affects 10 to 15% of MS patients, while the majority develops secondary progressive MS.
The company reports that recent therapeutic developments seek improve the tolerability of existing drugs, especially those based on interferon beta and glatiramer acetate. A focus on the development of anti-inflammatory drugs has also been observed.
Currently, the most effective treatment for MS in terms of controlling aspects of the immune system are disease modifying drugs, or ABCR treatment, where “A” stands for Avonex, “B” stands for Betaferon, “C” stands for Copaxone and “R” stands for Rebif. Avonex, Betaferon and Rebif are beta interferon drugs, while Copaxone has glatiramer acetate as an active ingredient.
“Physicians prefer Avonex, Betaferon, Copaxone, Rebif – or ABCRs – as first line therapy because of the 10 years of clinical data establishing their efficacy and safety,” said the study’s author, Frost & Sullivan Healthcare Industry Analyst Aish Vivekanandan in a news release. “As is evident, clinical data substantiating the benefits of drugs will prove to be the driving factor in enabling rapid approvals from regulatory agencies.”